Log in or Sign up for Free to view tailored content for your specialty!
Retina/Vitreous News
European Commission approves Vabysmo for retinal vein occlusion
The European Commission approved Vabysmo for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion, according to a press release from Roche.
ASRS 2024: Healio’s top videos so far
Healio’s top video perspectives from the American Society of Retina Specialists meeting highlight faricimab in diabetic macular edema as well as an axitinib implant for wet age-related macular degeneration.
Log in or Sign up for Free to view tailored content for your specialty!
VIDEO: Minimal IOP changes seen with aflibercept 8 mg or 2 mg at 48 weeks
In this Healio Video Perspective from the ASRS meeting, Jordana G. Fein, MD, MS, of Retina Group of Washington discusses IOP outcomes in patients with diabetic macular edema who were treated with aflibercept 8 mg or aflibercept 2 mg.
ASRS 2024: Healio’s top stories so far
Healio’s articles from the American Society of Retina Specialists meeting have covered long-term improvements with Luxturna and macular hole closure rates with different pars plana vitrectomy techniques.
BLOG: The good, the bad and the ugly in optometry news
Optometry in the 21st century has moved strongly toward evidence-based medicine, with the American Optometric Association even publishing a 14-step process to assist in the development of an evidence-based practice.
Sozinibercept combination therapy shows durability in patients with DME, neovascular AMD
Sozinibercept, a VEGF-C and -D “trap” inhibitor, showed improved durability in patients with retinal diseases when delivered as a combination therapy vs. anti-VEGF-A monotherapies, according to a study.
VIDEO: Comparable improvements seen with aflibercept 8 mg vs. 2 mg in DME
In this Healio Video Perspective from the ASRS meeting, Diana V. Do, MD, FASRS, of Byers Eye Institute discusses data from the PHOTON trial investigating aflibercept 8 mg and aflibercept 2 mg for the treatment of diabetic macular edema.
VIDEO: Macular neovascularization did not impact reduction in GA growth in GATHER trials
In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.
DPP-IV, SGLT2 and GLP-1 drugs do not increase risk for diabetic macular edema
Use of a DPP-IV inhibitor, SGLT2 inhibitor or GLP-1 receptor agonist does not increase risk for diabetic macular edema among adults with type 2 diabetes and diabetic retinopathy, according to study data.
Dropless vitrectomy for vitreous hemorrhage controls intraocular inflammation
A form of dropless vitrectomy helped control intraocular inflammation and prevent infection after surgery for vitreous hemorrhage secondary to proliferative diabetic retinopathy, according to a study.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read